Clinical Trials Detail

Targeted Therapy Directed by Genetic Testing in Patients With Solid Tumors, Lymphomas, or MM

Molecular Analysis for Therapy Choice (MATCH)

Objective
CategoryInformation
Study #: EAY131 - MATCH
Anatomic Site: Any
Histology: Histologically confirmed solid tumor or lymphoma or multiple myeloma
Mutation:
  • PI3K (mTOR; TSC 1/2; PTEN mutation or deletion; PTEN loss; PIK3CA; AKT mutations/amplifications
  • MAP Kinase pathway (BRAF, NRAS, NF1loss, GNAQ, GNA11; NF2 loss)
  • Growth Factors (EGFR; HER2 mutation; HER2 amplification; FGFR translocation/mutation; C-KIT; ALK translocation; ROS translocation; MET amplification; MET exon 14 skipping; Hedgehog pathway; NTRK fusions)
  • Cell cycle inhibtors (CCND1, 2, 3amplification; CDK4, CDK6 amplification)
  • DDR2 mutation
  • BRCA1
  • BRCA2
  • Mismatch repair
Stage: Advanced
Treatment Phase: Patients must have progressed following at least one line of standard systemic therapy or no standard treatment exists for their disease. Must have measurable disease.
Location:
Study Link: https://clinicaltrials.gov/ct2/show/NCT02465060?term=EAY131&rank=1

Clinical Trial Categories

  • Any